Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses
Key Takeaway: In this Phase III trial, the addition of ribociclib to fulvestrant maintained health-related quality of life (HRQOL) while improving progression-free survival. Time to definitive deterioration in global health status and pain trended in favor of the ribociclib group.
Study Design & Arms
Randomized 2:1 comparison of Ribociclib + Fulvestrant vs Placebo + Fulvestrant.
Study Population Distribution
Waffle chart representing the 2:1 randomization ratio (1 dot ≈ 2 patients).
Baseline Quality of Life Scores
Comparison of baseline EORTC QLQ-C30 Global Health and Pain scores (Mean ± SD).
Change in Pain Scores at 8 Weeks
Mean change from baseline (Negative values indicate improvement).
Risk of Deterioration (Hazard Ratios)
Hazard Ratio for Time to Definitive Deterioration (TTD) ≥10%. HR < 1 favors Ribociclib.
Metric Summary
Overview of all extracted metrics and their directionality.
Raw Data & Provenance
| ID | Metric | Group | Value | Source |
|---|